for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novocure Ltd

NVCR.O

Latest Trade

76.13USD

Change

0.00(0.00%)

Volume

247

Today's Range

--

 - 

--

52 Week Range

53.40

 - 

98.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
76.13
Open
0.00
Volume
247
3M AVG Volume
21.06
Today's High
--
Today's Low
--
52 Week High
98.84
52 Week Low
53.40
Shares Out (MIL)
101.09
Market Cap (MIL)
7,535.33
Forward P/E
784.63
Dividend (Yield %)
--

Next Event

Q3 2020 Novocure Ltd Earnings Release

Latest Developments

More

Novocure Q1 Net Profit $4Mln Versus -$12.2 Mln Loss Year Ago

Novocure Ltd Says At This Time, There Is No Material Impact To Co's Supply Chain

FDA Approves The Novottf-100Ltm System In Combination With Chemotherapy For The Treatment Of Malignant Pleural Mesothelioma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novocure Ltd

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Industry

Biotechnology & Drugs

Contact Info

Forum, NO. 4 Grenville Street

JE2 4UF

Jersey

+44.1534.756700

https://www.novocure.com/

Executive Leadership

William F. Doyle

Executive Chairman of the Board

Asaf Danziger

President, Chief Executive Officer, Director

Wilhelmus Groenhuysen

Chief Financial Officer

Ely Benaim

Chief Medical Officer

Michael J. Ambrogi

Chief Operating Officer

Key Stats

2.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.4K

2020(E)

0.5K
EPS (USD)

2017

-0.700

2018

-0.690

2019

-0.070

2020(E)

0.169
Price To Earnings (TTM)
25,267.80
Price To Sales (TTM)
18.42
Price To Book (MRQ)
28.12
Price To Cash Flow (TTM)
800.27
Total Debt To Equity (MRQ)
55.82
LT Debt To Equity (MRQ)
55.82
Return on Investment (TTM)
0.14
Return on Equity (TTM)
0.11

Latest News

Latest News

BRIEF-Novocure - 100 Physicians From 50 Cancer Treatment Centers In U.S. Certified To Prescribe Optune Lua

* NOVOCURE - OVER 100 PHYSICIANS FROM MORE THAN 50 CANCER TREATMENT CENTERS IN U.S. ARE CERTIFIED TO PRESCRIBE OPTUNE LUA Source text for Eikon: Further company coverage:

BRIEF-Novocure Q1 Net Profit $4Mln Versus -$12.2 Mln Loss Year Ago

* Q1 NET PROFIT 4.0 MILLION USD VERSUS -12.2 MILLION USD LOSS YEAR AGO

BRIEF-Novocure Announces Presentation Of EF-19 Post-Approval Registry Trial Data

* NOVOCURE ANNOUNCES PRESENTATION OF EF-19 POST-APPROVAL REGISTRY TRIAL DATA STUDYING OPTUNE AS A MONOTHERAPY FOR THE TREATMENT OF RECURRENT GBM AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 2020 VIRTUAL ANNUAL MEETING I

BRIEF-Novocure Ltd Says At This Time, There Is No Material Impact To Co's Supply Chain

* NOVOCURE LTD - AT THIS TIME, THERE IS NO MATERIAL IMPACT TO NOVOCURE'S SUPPLY CHAIN

BRIEF-Novocure Reports Qtrly Loss Per Share $0.23

* NOVOCURE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln

* NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING Source : https://bit.ly/2HiWTxC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma

* NOVOCURE REPORTS POSITIVE TOP-LINE RESULTS FROM STELLAR PHASE 2 PILOT TRIAL IN MESOTHELIOMA

BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide

* NCCN GUIDELINES RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS A CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12

* Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing

* NOVOCURE SECURES NEW $150 MILLION NON-DILUTIVE TERM LOAN FINANCING

BRIEF-Novocure Announces Q4 And FY17 Operating Statistics And Preliminary Revenue

* NOVOCURE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 OPERATING STATISTICS AND PRELIMINARY REVENUE

BRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

* NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

BRIEF-Novocure reports qtrly ‍loss per share $0.13​

* Novocure Ltd - Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up